
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 990 | 947 | 1063 | 887 | 2056 | 3433 |
Fund Return | -0.98% | -5.34% | 6.31% | -3.92% | 15.51% | 13.13% |
Place in category | 35 | 230 | 110 | 110 | 1 | 1 |
% in Category | 16 | 98 | 66 | 90 | 1 | 1 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
ICBCCS QY Medical Eq | 10.6B | 2.24 | -9.93 | - | ||
ICBCCS Innovation Power Eq | 5.74B | -2.41 | 5.68 | 0.31 | ||
ICBC Credit Literary Ids Eq | 5.6B | 7.24 | -1.38 | - | ||
ICBCCS China Core Value Mixed A | 4.05B | -1.50 | -8.72 | 4.38 | ||
SZSE Dividend Exchange Trade | 3.43B | -1.91 | -4.46 | 5.79 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fullgoal Tianding China Securities | 6.21B | -4.01 | 3.35 | 8.16 | ||
ICBCCS Innovation Power Eq | 5.74B | -2.41 | 5.68 | 0.31 | ||
Dacheng China Securities Dividend I | 3.69B | -4.37 | 4.26 | 8.23 | ||
SWS MU CSI 300 Value Index Fund | 2.68B | -3.14 | 3.69 | 6.55 | ||
Galaxy CSI 300 Value Index Fund | 2.57B | -3.13 | 4.40 | 6.34 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
China Merchants Shekou | CNE100002FC6 | 9.13 | 9.44 | +0.53% | |
China State Construction | CNE100000F46 | 9.13 | 5.51 | +1.29% | |
Poly Real Estate Group | CNE000001ND1 | 8.34 | 8.52 | +0.71% | |
Bank of Nanjing | CNE100000627 | 7.60 | 10.36 | +0.39% | |
Bank of Chengdu | CNE100002SN6 | 7.49 | 17.27 | -0.46% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Strong Buy |
Technical Indicators | Neutral | BUY | Strong Buy |
Summary | Neutral | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review